Trending in Oncology: SC Rybrevant, HER2 Combo Win, TNBC Filing and more

18 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Oncology Update spotlights global advances, led by FDA approval of subcutaneous Rybrevant FASPRO enabling five-minute dosing across amivantamab indications. Enhertu plus pertuzumab secures US first-line approval in HER2-positive metastatic breast cancer. EMA validates Datroway for first-line TNBC and backs a Phase 3 VCN-01 study in metastatic PDAC. Canada recommends Opdivo plus Yervoy in MSI-H or dMMR mCRC, and British Columbia will reimburse Fruzaqla. FDA grants Breakthrough Therapy Designation to JSKN003 and converts rucaparib to regular approval. Japan approves Zynyz combination for SCAC. J&J acquires Halda.
Categoria
Oncology
Commenta per primo questo video.

Prossimo